Immuron Ltd (IMRN) Form 6-K — Sep 3, 2026
Immuron Limited (NASDAQ: IMRN; ASX: IMC) announced it has executed an exclusive distribution agreement with Sweden's Calmino group AB to launch PROIBS in the United States, following the product's Australian launch during FY26. PROIBS is a European-certified medical device for abdominal pain, bloating, and unsettled bowel movements, containing AVH200 derived from Aloe barbadensis, and targets a US digestive/gut health supplement market Immuron cites at $4.16 billion. The product has been on the Swedish pharmacy market for more than a decade.
Key figures
- Pct would recommend
- 98
- Pct users found helpful
- 94
- Pct daily life improvement
- 91
- Usability study participants
- 1003
- Us digestive gut health market
- $4.16 billion
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.